Please login to the form below

Not currently logged in
Email:
Password:

Saizen

This page shows the latest Saizen news and features for those working in and with pharma, biotech and healthcare.

Merck completes €15m Spanish biotech facility expansion

Merck completes €15m Spanish biotech facility expansion

The Tres Cantos plant is Merck's main site for the production of active substances in its fertility treatment Gonal-f and endocrine and metabolic disorders treatment Saizen, for which global

Latest news

  • Sales down at Merck Serono on Rebif pressure Sales down at Merck Serono on Rebif pressure

    Among its other products, sales of Merck Serono's fertility treatment Gonal-f (follitropin alfa) slipped fractionally to 137m while growth hormone Saizen (somatropin) brought in 61m, in line with one

  • Merck KGaA to meet 2014 financial targets one year early Merck KGaA to meet 2014 financial targets one year early

    This performance helped offset declines for other key brands, such as fertility treatment Gonal-f (follitropin alfa) and growth hormone product Saizen (somatropin), down 4 and 8 per cent to 145m

  • Merck Serono to invest €150m in China R&D

    The Swiss-based company's key products Erbitux (cancer), Rebif (multiple sclerosis), Gobal-f (infertility), Saizen (endocrine and metabolic disorders) and Concor and Euthyrox (cardiometabolic diseases) are already available in the

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....